Compare LQDA & MMYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | MMYT |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.4B |
| IPO Year | 2020 | 2010 |
| Metric | LQDA | MMYT |
|---|---|---|
| Price | $78.03 | $52.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | $41.00 | ★ $101.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $278.87 | $16.83 |
| Revenue Next Year | $57.13 | $17.24 |
| P/E Ratio | $147.92 | ★ $107.67 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $11.85 | $32.67 |
| 52 Week High | $78.25 | $104.99 |
| Indicator | LQDA | MMYT |
|---|---|---|
| Relative Strength Index (RSI) | 75.44 | 69.09 |
| Support Level | $31.23 | $38.67 |
| Resistance Level | N/A | $58.18 |
| Average True Range (ATR) | 4.14 | 2.97 |
| MACD | 0.40 | 1.09 |
| Stochastic Oscillator | 91.55 | 93.19 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.